Fluorodopa

Source: Wikipedia, the free encyclopedia.
Not to be confused with Florbetapir (18F).

Fluorodopa
Clinical data
Trade namesFluorodopa F18
Other names6-fluoro-L-DOPA, FDOPA
License data
Intravenous
ATC code
Legal status
Legal status
Identifiers
  • (2S)-2-amino-3-(2-(18F)fluoranyl-4,5-dihydroxyphenyl)propanoic acid
JSmol)
  • C1=C(C(=CC(=C1O)O)F)CC(C(=O)O)N
  • InChI=1S/C9H10FNO4/c10-5-3-8(13)7(12)2-4(5)1-6(11)9(14)15/h2-3,6,12-13H,1,11H2,(H,14,15)/t6-/m0/s1/i10-1
  • Key:PAXWQORCRCBOCU-RPDRGXCHSA-N

Fluorodopa, also known as FDOPA, is a fluorinated form of

radiotracer in positron emission tomography (PET).[1]

The most common side effects are injection site pain.[2]

Medical uses

Fluorodopa is indicated for use in positron emission tomography (PET) to visualize

Parkinsonian syndromes (PS).[2]

History

In October 2019, Fluorodopa was approved in the United States for the visual detection of certain nerve cells in adult patients with suspected Parkinsonian Syndromes (PS).[3][4]

The U.S. Food and Drug Administration (FDA) approved Fluorodopa F 18 based on evidence from one clinical trial of 56 patients with suspected PS.[3] The trial was conducted at one clinical site in the United States.[3]

References

  1. doi:10.1016/S0957-4166(02)00321-X
    .
  2. ^ a b "Fluorodopa F18 injection". DailyMed. 12 October 2019. Retrieved 26 April 2020.
  3. ^ a b c "Drug Trials Snapshots: Fluorodopa F 18". U.S. Food and Drug Administration (FDA). 27 November 2019. Archived from the original on 27 November 2019. Retrieved 27 November 2019. Public Domain This article incorporates text from this source, which is in the public domain.
  4. ^ "Drug Approval Package: Fluorodopa F18". U.S. Food and Drug Administration (FDA). 20 November 2019. Archived from the original on 27 November 2019. Retrieved 26 November 2019. Public Domain This article incorporates text from this source, which is in the public domain.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Fluorodopa&oldid=1214633391"